The molecular transition from physiological NRF2 regulation to its pathogenic activation in cancer is illustrated in Figure 1, which contrasts the normal KEAP1-dependent ubiquitination and transient antioxidant response with the sustained, mutation-driven NRF2 hyperactivation observed in advanced tumors. Here, NFE2L2 is linked to cancer.